The era of exclusivity for semaglutide in Brazil has come to a formal close. Following the March 20 expiration of the patent for the active ingredient behind Novo Nordisk’s blockbuster drugs Ozempic and Wegovy, the Danish pharmaceutical giant is shifting from a defensive legal strategy to an offensive commercial one. Having lost its bid to extend patent protection in the Brazilian courts, the company is now preparing for a market soon to be crowded with generic alternatives.
To navigate this transition, Novo Nordisk has entered into a strategic partnership with Eurofarma, one of Brazil’s most formidable pharmaceutical players. The move is designed to leverage Eurofarma’s deep local distribution networks and manufacturing expertise. By aligning with a domestic powerhouse, Novo Nordisk aims to secure its foothold before the inevitable arrival of competing "weight-loss pens," effectively choosing to manage the market's expansion rather than simply watching its monopoly erode.
This pivot reflects a broader reality in the global pharmaceutical industry: the patent cliff is no longer just a threat to be litigated, but a landscape to be managed through savvy localization. In Brazil, where demand for metabolic treatments is surging, the collaboration between the global leader in GLP-1 agonists and a local champion marks a new chapter in how high-demand biologics are commercialized in emerging markets.
With reporting from NeoFeed.
Source · NeoFeed
